Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 02, 2024 09:05 ET
|
Kriya Therapeutics, Inc.
– Kriya is developing KRIYA-825 as a potential one-time gene therapy expressing a fusion protein inhibiting the activity of complement C3 and C5 for the treatment of Geographic Atrophy – PALO...
Kriya Announces Six Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024
April 22, 2024 16:30 ET
|
Kriya Therapeutics, Inc.
– Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic disease and neurology – – Company to host symposium on “Advancing Gene...
Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 09:00 ET
|
Kriya Therapeutics, Inc.
– Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
January 05, 2024 09:00 ET
|
Kriya Therapeutics, Inc.
– KRIYA-586 is designed to be a one-time treatment delivered by focal peribulbar injection, that encodes an antibody blocking the Insulin-Like Growth Factor 1 Receptor (IGF-1R), a clinically validated...
Kriya to Present at the J.P. Morgan 42nd Annual Healthcare Conference
December 20, 2023 08:30 ET
|
Kriya Therapeutics, Inc.
PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common...
Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy
September 27, 2023 08:30 ET
|
Kriya Therapeutics, Inc.
– Everads' next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which Kriya intends to use for multiple ophthalmology gene therapy product candidates – ...
Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases
September 06, 2023 08:30 ET
|
Kriya Therapeutics, Inc.
– Kriya envisions treating people with NASH using a one-time intramuscular gene therapy enabling continuous expression of native FGF21 – – Kriya anticipates advancing its NASH gene therapy candidate...
Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases
July 26, 2023 08:25 ET
|
Kriya Therapeutics, Inc.
– Kriya's therapeutic pipeline addresses a broad range of diseases that collectively affect millions of patients worldwide—with a goal of delivering transformational clinical benefits with one-time...